Friday, January 30, 2026

Controversial Martial Law Crisis: Over 60,000 Rounds of Ammunition Transported

During South Korea's martial law crisis, over 60,000 rounds of ammunition were transported, including prohibited HP rounds, raising concerns.

Tesla Accelerates Battery Innovation With Dry Electrode Tech Promising 30% Cost Cut

Tesla plans to implement a dry battery electrode process this year, potentially reducing costs by 30%, but commercialization remains uncertain.

Trump’s New Tariff War: How U.S. Trade Policy Is Forcing Korean Automakers to American Soil

U.S. tariffs on Korean exports surged nearly 47-fold during Trump's administration, impacting competitiveness and requiring urgent policy support.

Tag: Novo Nordisk

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Novo Nordisk’s Wegovy Pill Draws 3,000 Prescriptions in Its First Week—Is Oral GLP-1 Here to Stay?

Novo Nordisk's Wegovy oral obesity treatment saw over 3,000 prescriptions in its first week, indicating strong market demand.

Patches, Implants, and Oral Films… The Drug-Delivery Format Battle After Oral Wegovy

Oral Wegovy's launch is transforming obesity treatment, focusing on user-friendly delivery methods and enhancing patient adherence.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.